Co-Authors
This is a "connection" page, showing publications co-authored by David De Bels and Luc Kugener.
Connection Strength
2.017
-
SARS-CoV-2 infection as a risk factor for herpesviridae reactivation: consider the potential influence of corticosteroid therapy. Crit Care. 2020 10 22; 24(1):623.
Score: 0.227
-
Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider. Crit Care. 2020 10 09; 24(1):603.
Score: 0.227
-
TPE seems to be a treatment that may improve outcomes by effectively removing fibrin degradation products and restoring coagulation status: fact or fiction? Crit Care. 2020 10 06; 24(1):599.
Score: 0.227
-
Plasma exchange in critically ill COVID-19 patients improved inflammation, microcirculatory clot formation, and hypotension, thereby improving clinical outcomes: fact or fiction? Crit Care. 2020 09 07; 24(1):551.
Score: 0.225
-
Compared to NIPPV, HFNC is more dangerous regarding aerosol dispersion and contamination of healthcare personnel: we are not sure. Crit Care. 2020 08 04; 24(1):482.
Score: 0.224
-
Inhibiting IL-6 in COVID-19: we are not sure. Crit Care. 2020 07 27; 24(1):463.
Score: 0.224
-
Liver injury without liver failure in COVID-19 patients: how to explain, in some cases, elevated ammonia without hepatic decompensation. Crit Care. 2020 06 16; 24(1):352.
Score: 0.222
-
With the current COVID pandemic: should we use single-use flexible bronchoscopes instead of conventional bronchoscopes? Crit Care. 2020 05 18; 24(1):234.
Score: 0.221
-
Therapeutic plasma exchange as a routine therapy in septic shock and as an experimental treatment for COVID-19: we are not sure. Crit Care. 2020 05 15; 24(1):226.
Score: 0.221